Personal Profile

Dr Suraiya Dubash is a consultant in clinical oncology specialising in the treatment and care of patients with lung cancer, thymoma, and thymic cancers. She is the lead for stereotactic radiotherapy services at Mount Vernon Cancer Centre and holds an honorary clinical senior lecturer position at Imperial College London, collaborating with the cancer imaging group to advance oncology through research and education.

She began her academic journey at St. Bartholomew’s and the Royal London Hospital. She completed her oncology training at Imperial College London and Mount Vernon Cancer Centre. Her dedication to advancing cancer treatment is exemplified by her PhD in clinical cancer imaging from Imperial College London, where her research focused on functional imaging (PET/CT and MRI), biomarker and radiopharmaceutical development, and the use of AI in oncology. 

She is active in clinical research and teaching. She has been principal investigator on a range of clinical trials within the national portfolio and an advisor to pharmaceutical companies on new treatments. She has been recognised with several prestigious awards from organisations such as NCRI, BNMS, JNM, and has published extensively in peer-reviewed journals. 

Her clinical expertise includes chemotherapy, biological therapy, immunotherapy, and radiotherapy. She is proficient in advanced radiotherapy techniques such as intensity modulated radiotherapy (IMRT), volumetric arc therapy (VMAT),  image guided radiotherapy (IGRT), deep inspiration breath hold (DIBH), and stereotactic radiotherapy.

Clinical Interests

Lung cancer, Thymoma and Thymic cancers.

Chemotherapy, biological therapy, immunotherapy, and radiotherapy. 

Advanced radiotherapy techniques such as intensity modulated radiotherapy (IMRT), volumetric arc therapy (VMAT),  image guided radiotherapy (IGRT), deep inspiration breath hold (DIBH), and stereotactic radiotherapy.

Professional Memberships

General Medical Council 

British Medical Association 

Medical Defence Union 

The European SocieTy for Radiotherapy and Oncology